NCT05234723
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
Recruiting
Not specifiedAges 18+ObservationalIRCCS Azienda Ospedaliero-Universitaria di BolognaInvestigator-initiated
~100 participants
Updated 2026-06-15 on ClinicalTrials.gov
At a glance
Recruiting sites
7 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To define incidence of GCV-RR CMV-infection in SOT and HSCT patients
Measured over Through study completion, an average of 1 year
+1 more outcome measured
Conditions
Where it's being run
23 sites across 13 statesItaly7
Spain4
Belgium2
Texas1
Helsinki1
Limoges1
Bologna1
Milano1
Study leadership
- Renato Pascale, MD · PRINCIPAL_INVESTIGATOR · IRCCS AOUBO
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
Ability to understand the purpose of the study and provide signed and dated informed consent
Exclusion
Lack of clinical and/or laboratory data regarding the type of CMV event
Lack of the serological mismatch at transplantation
Lack of the type of SOT or HSCT
Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis
What this trial measures
- To define incidence of GCV-RR CMV-infection in SOT and HSCT patientsThrough study completion, an average of 1 year
To define incidence of GCV-RR CMV-infection in SOT and HSCT patients
- To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patientsThrough study completion, an average of 1 year
To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients